Dendron Corporation (DNDN) is a biotechnology company that researches and develops potential treatments for various types of cancers. According to the Dendron Corporation (DNDN) Fact Sheet, Dendron Corporation (DNDN) explores the application of ACI (active cellular immunotherapy) to the potential treatment of cancers. Dendron Corporation (DNDN) uses ACI to engage the immune system and stimulate a tumor-directed response. By “reigniting” the patient’s immune system, Dendron Corporation (DNDN) believes ACI can provide those suffering with a new treatment for cancer.
In November 2014 Dendron Corporation (DNDN) filed for Chapter 11 bankruptcy. In February 2015, Dendron Corporation (DNDN) was purchased at auction by Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals paid $400 million in cash for Dendron Corporation (DNDN). Valeant Pharmaceuticals terminated Dendron Corporation (DNDN) CEO Thomas Amick, and 77 others after the purchase.
Dendron Corporation (DNDN) was offered by various stock brokers and brokerage firms. Dendron Corporation (DNDN) is a speculative, high risk investment that is not suitable for all investors.
If you, or someone you know has lost money investing in Dendron Corporation (DNDN) through a broker-dealer firm, you may be entitled to full recovery of your losses. The attorneys at Fitapelli Kurta prosecute cases on behalf of investors like you who have lost money as a result of unsuitable investments. These cases are taken on a contingency fee basis only, which means our firm will not receive any compensation whatsoever unless and until you recover money.
Cases are filed with the Financial Industry Regulatory Authority (FINRA) and will submit to arbitration. Fitapelli Kurta has filed hundreds of cases before FINRA and has recovered millions on behalf of investors who have fallen victim to broker misconduct. Do not delay. Call 877 – 238 – 4175 to speak directly to an attorney and further discuss the merits of your case.
Our consultations are always free.
Call 877 – 238 – 4175 now.